DiscoverEnterprise Podcast NetworkIPA’s Innovative Approach to Antibody Discovery and AI Integration
IPA’s Innovative Approach to Antibody Discovery and AI Integration

IPA’s Innovative Approach to Antibody Discovery and AI Integration

Update: 2024-11-30
Share

Description



Jennifer Bath, CEO and President of IPA (ImmunoPrecise Antibodies Ltd), an AI-driven bio-therapeutic research and technology company joins Enterprise Fit Radio.

Listen to host Eric Dye & guest Jennifer Bath discuss the following:



* You’ve had such an impressive journey, from academia to leadership roles in biotech and contract research. How has your background in immunology and biochemistry shaped your approach as CEO of IPA?

* And with such diverse experience, how do you balance the science with the business side to drive innovation and growth?

* What sets IPA apart in the world of drug discovery? How is your approach different from others in the field?

* And just to dive a little deeper, can you share an example of how your unique approach has made a tangible impact on a project or partnership?

* How do you see AI reshaping the drug discovery process, especially in antibody development? What’s the most exciting breakthrough you’ve seen so far?

* I saw that IPA recently announced some exciting news with the Mayo Clinic about anti-aging research. It sounds like a game-changer, especially with AI technology poised to tap into an $81 billion market. Can you tell us more about what’s going on there?





Jennifer Bath is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. There, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology, and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.



Website: https://www.ipatherapeutics.com

Social Media Links:

Linkedin: https://www.linkedin.com/company/immunoprecise-antibodies-ltd./

X: https://x.com/immunoprecise

Youtube: CLICK HERE



People also listened to: Leadership Orbit: Infinite Leadership Potential for Sustainable Progress
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

IPA’s Innovative Approach to Antibody Discovery and AI Integration

IPA’s Innovative Approach to Antibody Discovery and AI Integration

EPN